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Abstract
Background:  There has not been a comprehensive, multi-centre study of streptococcal
peritonitis in patients on peritoneal dialysis (PD) to date.
Methods: The predictors, treatment and clinical outcomes of streptococcal peritonitis were
examined by binary logistic regression and multilevel, multivariate poisson regression in all
Australian PD patients involving 66 centres between 2003 and 2006.
Results:  Two hundred and eighty-seven episodes of streptococcal peritonitis (4.6% of all
peritonitis episodes) occurred in 256 individuals. Its occurrence was independently predicted by
Aboriginal or Torres Strait Islander racial origin. Compared with other organisms, streptococcal
peritonitis was associated with significantly lower risks of relapse (3% vs 15%), catheter removal
(10% vs 23%) and permanent haemodialysis transfer (9% vs 18%), as well as a shorter duration of
hospitalisation (5 vs 6 days). Overall, 249 (87%) patients were successfully treated with antibiotics
without experiencing relapse, catheter removal or death. The majority of streptococcal peritonitis
episodes were treated with either intraperitoneal vancomycin (most common) or first-generation
cephalosporins for a median period of 13 days (interquartile range 8–18 days). Initial empiric
antibiotic choice did not influence outcomes.
Conclusion: Streptococcal peritonitis is a not infrequent complication of PD, which is more
common in indigenous patients. When treated with either first-generation cephalosporins or
vancomycin for a period of 2 weeks, streptococcal peritonitis is associated with lower risks of
relapse, catheter removal and permanent haemodialysis transfer than other forms of PD-associated
peritonitis.
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Background
Streptococcal peritonitis accounts for between 6% and
16% of peritoneal dialysis (PD)-associated peritonitis
[1,2] and is generally reported to be severe [3]. The 2005
update of the International Society of PD (ISPD) Guide-
lines for Management of PD-related Infections recom-
mends that streptococcal peritonitis is best treated with
intraperitoneal ampicillin for a period of 3 weeks [3].
However, these recommendations are based on limited
observations, mostly in the form of case reports or small
case series [1,4-10], some of which have been potentially
confounded by the inclusion of enterococci (previously
called non-haemolytic streptococci and now recognised
to be a separate genus of Gram-positive cocci). Moreover,
there has not previously been a comprehensive examina-
tion of different therapeutic approaches to streptococcal
peritonitis.
The aim of the current study was to examine the fre-
quency, predictors, treatment and clinical outcomes of
streptococcal peritonitis in all Australian PD patients
involving 66 PD centres.
Methods
Study Population
The study included all Australian adult patients from the
ANZDATA Registry who were receiving PD between 1st
October 2003 (when detailed peritonitis data started to be
collected) and 31st December 2006. Ethical approval for
the use of registry data was obtained from the Princess
Alexandra Hospital Human Research Ethics Committee.
The data collected included demographic data, cause of
primary renal disease, co-morbidities at the start of dialy-
sis (coronary artery disease, peripheral vascular disease,
cerebrovascular disease, chronic lung disease, diabetes,
hypertension, and smoking status), body mass index
(BMI), late referral (defined as commencement of dialysis
within 3 months of referral to a nephrologist), microbiol-
ogy of peritonitis episodes (up to three organisms for pol-
ymicrobial episodes) and the initial and subsequent
antibiotic treatment regimens. Diagnosis of streptococcal
peritonitis was made based on a PD effluent white cell
count >100/μl with >50% polymorphonuclear leucocytes
and isolation of Streptococcus species from dialysate cul-
ture. Enterococci, which are now recognised as a separate
genus of Gram-positive cocci, were not included. In cases
of polymicrobial peritonitis, streptococcal peritonitis was
recorded if a streptococcal species was at least 1 of the iso-
lated organisms. Centre size was categorised according to
quartiles of the numbers of patients cared for by individ-
ual units over the duration of the study: small (<11
patients), small-medium (11 – 38 patients), medium-
large (39 – 98 patients) and large (>99 patients).
The outcomes examined were peritonitis relapse, repeat
peritonitis, peritonitis-associated hospitalization, catheter
removal, temporary or permanent transfer to haemodial-
ysis, and patient death. Peritonitis relapse was defined as
an episode of peritonitis occurring within 4 weeks of the
last antibiotic dose (or within 5 weeks if intermittent van-
comycin used) for peritonitis due to the same organism.
Repeat peritonitis was defined as an episode of peritonitis
occurring more than 4 weeks after the last antibiotic dose
(or more than 5 weeks if intermittent vancomycin was
used) for peritonitis due to the same organism.
Statistical analysis
Results were expressed as frequencies and percentages for
categorical variables, mean ± standard deviation for con-
tinuous variables, and median and interquartile range for
non-parametric data. Differences between 2 groups of
patients were analysed by chi-square test for categorical
data, unpaired t-test for continuous parametric data and
Mann-Whitney test for continuous nonparametric data.
The independent predictors of streptococcal peritonitis
were determined by multivariate multilevel mixed-effects
poisson regression: this hierarchical model took into
account clustering based on state of residence, treating
unit and individual patient [11]. Predictors of peritonitis
outcomes were assessed by multivariable binary logistic
regression. Data were analysed using the software pack-
ages SPSS for Windows release 12.0 (SPSS Inc., North Syd-
ney, Australia) and Stata/SE 10.1(College Station, Tx). P
values less than 0.05 were considered statistically signifi-
cant.
Results
Population Characteristics
A total of 4675 patients received peritoneal dialysis in
Australia during the study period (1 October 2003 to 31
December 2006). They were followed for 6002 patient-
years. Two hundred and eighty-seven episodes of Strepto-
coccal peritonitis occurred in 256 individuals. Streptococ-
cal species accounted for 4.6% of all 3594 peritonitis
episodes. The rates of all peritonitis and streptococcal
peritonitis were 0.60 and 0.05 episodes per patient-year of
treatment, respectively. Additional non-streptococcal
organisms were isolated in 66 (23%) episodes of strepto-
coccal peritonitis, including coagulase negative staphylo-
cocci (n = 17), S. aureus (n = 8), enterococci (n = 4),
Corynebacterium (n = 1), other Gram-positive organisms
(n = 2), Pseudomonas (n = 2), Acinetobacter (n = 1), E. coli
(n = 14), Klebsiella (n = 5), Serratia (n = 1), Proteus (n = 1),
Enterobacter (n = 1), Neisseria (n = 4), other Gram-negative
organisms (n = 2), Candida (n = 3) and other organisms
(n = 2). Fifty-seven episodes of peritonitis were associated
with 2 organisms, and 9 episodes were associated with 3
organisms. Two hundred and twenty-eight patients expe-
rienced 1 episode of streptococcal peritonitis during theBMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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study period, 26 experienced 2 episodes, 1 experienced 3
episodes and 1 experienced 4 episodes.
Predictors of Streptococcal peritonitis
The characteristics of patients who did and did not expe-
rience streptococcal peritonitis are shown in Table 1. On
univariate analysis, patients who experienced streptococ-
cal peritonitis during the study period were more likely to
be indigenous (Aboriginal and Torres Strait Islander and
Maori and Pacific Islander peoples) or Asian, be referred
to a renal unit within 3 months of commencing renal
replacement therapy and have a baseline PET demonstrat-
ing low average peritoneal transport status. The hierarchi-
cal multivariate poisson model showed that the only
independent predictor of streptococcal peritonitis inci-
dence was Aboriginal/Torres Strait Islander racial origin
(adjusted incidence rate ratio (IRR) 1.75, 95% CI 1.008 –
3.03; p = 0.047). The development of streptococcal peri-
tonitis was not associated with age, gender, BMI, kidney
function at dialysis commencement, current smoking sta-
tus, chronic lung disease, coronary artery disease, periph-
eral vascular disease, cerebrovascular disease, diabetes
mellitus, ESRF, or late referral within 3 months of needing
to start dialysis.
Effect of previous peritonitis episodes on occurrence of 
Streptococcal peritonitis
A history of previous peritonitis was less common for
streptococcal than non-streptococcal peritonitis episodes
(39% vs 45%, respectively, p < 0.05). Moreover, the time
elapsed between a prior peritonitis episode and the subse-
quent one was significantly longer for streptococcal peri-
tonitis (median period 140 days, interquartile range [IQR]
65.75–311.5 days) than non-streptococcal peritonitis
(median 74 days, IQR 34.75–175 days, p = 0.4). Conse-
quently, the probability of an episode of subsequent peri-
tonitis being caused by a streptococcal species as opposed
to an organism other than streptococcus significantly
increased over time from 7% in the first 60 days to 6% in
the first year to 11% after the first year (p < 0.05).
Treatment of Streptococcal peritonitis
The vast majority of patients with Streptococcal peritonitis
were initially treated with either intraperitoneal vancomy-
cin or cephazolin in combination with gentamicin as
empiric therapy (Table 2). Once culture results became
known at a median time of 3 days, approximately one-
third of patients were changed to vancomycin mono-
therapy (27%) or cephalothin monotherapy (8%). Oral
antibiotics were prescribed at some stage during the treat-
ment of streptococcal peritonitis in a minority of patients,
the most common ones being cephalexin (11%), cipro-
floxacin (8%), amoxycillin plus clavulanate (6%), amox-
ycillin (5%), metronidazole (3%) and flucloxacillin
(3%). Overall, the median total antibiotic course duration
was 13 days (Table 3). Heparin was administered to dia-
lysate in 28 (10%) episodes of streptococcal peritonitis.
Streptokinase was not instilled in the PD catheter in any
episodes of streptococcal peritonitis and only 28 (10%)
patients with streptococcal peritonitis received concomi-
tant prophylactic nystatin therapy.
Outcomes of streptococcal peritonitis
Compared with non-streptococcal peritonitis, streptococ-
cal peritonitis was associated with significantly lower risks
of relapse (3% vs 15%), catheter removal (10% vs 23%)
and permanent haemodialysis transfer (9% vs 18%), as
well as a shorter duration of hospitalisation (Table 3). The
risk of death was lower with streptococcal peritonitis,
although the difference was not statistically significant.
Overall, 249 (87%) patients with streptococcal peritonitis
were successfully treated with antibiotics without experi-
encing relapse, catheter removal or death.
The administration of vancomycin, cephalosporin or
another agent in the initial or subsequent empiric antibi-
otic regimens did not significantly influence streptococcal
peritonitis outcomes on either univariate or multivariate
analyses. Longer antibiotic course duration was associated
with higher risks of hospitalisation (OR 1.02 per day, 95%
CI 1.008–1.02), catheter removal (OR 1.01, 95% CI
1.004–1.02) and permanent haemodialysis transfer (OR
1.01, 95% CI 1.003–1.01), presumably reflecting the
medical treatment response to more severe peritonitis epi-
sodes. Using binary logistic regression, catheter removal
was independently predicted by increasing age (OR 1.03
per year, 95% CI 1.0–1.07), female gender (OR 0.35, 95%
CI 0.13–0.99), missing baseline PET data (OR 9.15, 95%
CI 1.93–43.5), high average transport status (OR 4.12,
95% CI 1.10–15.4) and polymicrobial peritonitis (OR
7.77, 95% CI 3.00–20.1). Permanent haemodialysis
transfer was independently predicted by higher BMI (OR
1.10 per kg/m2, 95% CI 1.01–1.28), missing baseline PET
data (OR 9.78, 95% CI 2.36–40.6) and polymicrobial
peritonitis (OR 9.84, 95% CI 3.71–26.1). No other varia-
bles were independently associated with either of these
outcomes and there were no significant independent pre-
dictors of streptococcal peritonitis relapse, hospitalisation
or death.
Discussion
The present study, involving 287 cases of PD-associated
streptococcal peritonitis across 66 different PD centres,
represents the largest examination to date of the fre-
quency, predictors, treatment and clinical outcomes of
this important condition. The key findings were that
streptococcal peritonitis accounted for just under 5% of
all peritonitis episodes in Australia and was associated
with significantly lower risks of relapse (3% vs 15%), cath-
eter removal (10% vs 23%) and permanent haemodialysisBMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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Table 1: Characteristics of all Australian PD patients who did and did not experience streptococcal peritonitis at any stage during the 
period 2003–2006.
Characteristic Streptococcal peritonitis
(n = 256)
No Streptococcal peritonitis
(n = 4419)
p Value
Age (years) 62.4 ± 15.8 61.5 ± 16.8 0.4
Women 134 (52%) 2415 (55%) 0.5
Racial origin 0.005
Caucasian 176 (69%) 3405 (77%)
Aboriginal/Torres Strait Islander 28 (11%) 333 (8%)
Maori/Pacific Islander 8 (3%) 100 (2%)
Asian 37 (14%) 404 (9%)
Other 7 (3%) 177 (4%)
BMI (kg/m2) 25.8 ± 5.1 25.9 ± 6.5 0.9
eGFR at dialysis start
(mL/min/1.73 m2)
6.8 ± 4.3 7.1 ± 4.5 0.4
Late referral 74 (29%) 1037 (24%) 0.047
ESRF Cause 0.4
Chronic glomerulonephritis 75 (29%) 1248 (28%)
Diabetic nephropathy 79 (31%) 1240 (28%)
Renovascular disease 32 (13%) 607 (14%)
Polycystic kidneys 17 (7%) 239 (5%)
Reflux nephropathy 12 (5%) 185 (4%)
Other 23 (9%) 622 (14%)
Unknown 18 (7%) 278 (12%)
Current smoker 26 (10%) 531 (12%) 0.2
Chronic lung disease 32 (13%) 567 (13%) 0.9
Coronary artery disease 99 (39%) 1568 (35%) 0.3
Peripheral vascular disease 59 (23%) 987 (22%) 0.8
Cerebrovascular disease 27 (11%) 581 (13%) 0.2
Diabetes mellitus 100 (39%) 1638 (37%) 0.5
Peritoneal Transport Status <0.001
High 31 (12%) 440 (10%)
High average 94 (37%) 1617 (37%)
Low average 86 (34%) 992 (22%)
Low 12 (5%) 186 (4%)
Unknown/Not specified 33 (13%) 1184 (27%)
Centre size (no. PD patients) 0.7
Small (≤ 10) 2 (1%) 53 (1%)
Small-Med (11–38) 15 (6%) 306 (7%)
Med-Large (39–98) 52(20%) 976 (22%)
Large (≥ 99) 187 (73%) 3084 (70%)BMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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transfer (9% vs 18%) than other forms of PD-associated
peritonitis. Additional organisms were isolated in 23% of
streptococcal peritonitis episodes and 21% of patients
experienced more than one episode of streptococcal PD
peritonitis.
These findings are in keeping with those of Shukla et al
[1], who undertook a 10-year review of 104 episodes of
streptococcal PD peritonitis at a single centre between
1995 and 2005. They observed that streptococcal perito-
nitis was associated with good outcomes with a relapse
rate of 7.6%, catheter removal rate of 4.8% and median
duration of hospitalisation of 8 days. Approximately one-
third of patients experienced more than one episode of
streptococcal peritonitis and additional organisms were
isolated in 16.3% of episodes. Interestingly, Shukla and
coworkers observed that streptococcal peritonitis
accounted for a much higher proportion of total peritoni-
tis episodes than in our study (11.7% vs 4.6%) and that
the incidence increased from 6% in 1995–1996 to 12–
16% from 1997–2005. They attributed this rise to the
introduction of the Y-set system and the use of mupirocin
for routine exit site care, which may have selectively sup-
pressed staphylococcal infections resulting in an appar-
ently higher proportion of non-staphylococcal peritonitis.
In contrast, less than a third of PD units in Australia regu-
larly use mupirocin prophylaxis, which may have
accounted for part of the disparity in streptococcal perito-
nitis prevalences between our study and that of Shukla et
al. Nevertheless, the rate of streptococcal peritonitis in our
study (0.05 episodes per patient-year) was relatively low.
Previous studies have suggested that streptococcal perito-
nitis accounts for between 6% and 16% of all PD perito-
nitis [1,10,12-14]. Some of this apparent disparity in
results may be accounted for by the universal use of twin-
bag systems in Australia and the exclusion of enterococci,
which were previously considered to be non-haemolytic
strepotococci, but are now recognised as a separate genus
of Gram-positive cocci [15]. For example, Munoz de Bus-
tillo et al [10] observed 58 episodes of streptococcal PD
peritonitis between 1980 and 1995, accounting for 12%
of all peritonitis episodes, and reported that streptococcal
peritonitis was associated with a delayed treatment rep-
sonse. However, 19 (32.7%) of these episodes were
caused by Enterococcus faecalis, such that true streptococcal
peritonitis actually accounted for approximately 8% of
total peritonitis episodes. Moreover, E. faecalis is known
to be a more virulent organism than streptococci and
therefore likely to have biased reporting of streptococcal
peritonitis outcomes in an adverse direction.
A novel finding of our study was that streptococcal perito-
nitis was independently predicted by Aboriginal or Torres
Strait Islander racial background. The influence of demo-
graphic variables such as race has not been previously
studied, although streptococcal skin infections are
reported to be much more frequent in Aboriginal or
Torres Strait Islander peoples than the rest of the Austral-
ian population [16,17]. Socioeconomic factors, such as
housing conditions, and remoteness of living are likely to
be important contributors to the increased risk of strepto-
coccal peritonitis in the present study, but could not be
evaluated due to the limited data collected by the ANZ-
DATA Registry.
In contrast to previous studies [10], we did not find an
increased incidence of streptococcal peritonitis in females.
This gender difference has previously been attributed to
colonisation of streptococcal organisms in the female gen-
ital tract [4,6], but could have been potentially influenced
by the inclusion of enterococci. This factor may also have
explained the finding by Munoz de Bustillo et al [10] that
streptococcal peritonitis is associated with increasing age,
since enterococci are associated with bowel pathology
that is found more commonly in older individuals.
Prior episodes of peritonitis have previously been
reported as a risk factor for streptococcal peritonitis [10],
whereas we found that a history of peritonitis was not pre-
dictive and, in fact, the time between episodes of peritoni-
tis was longer in streptococcal cases. This observation may
be related to the fact that prior antibiotic treatment for
peritonitis may influence peritonitis risk in favour of
other organisms, such as fungi, early on [18,19]. Others
have found duration of peritoneal dialysis to be the most
predictive risk factor for failure of treatment response with
streptococcal peritonitis [13], which was not supported by
State 0.2
New South Wales 101 (39%) 1731 (39%)
Northern Territory 5 (2%) 80 (2%)
Queensland 52 (20%) 903 (20%)
South Australia 20 (1%) 275 (6%)
Tasmania 3(1%) 74 (2%)
Victoria 40 (16%) 920 (21%)
Western Australia 35 (14%) 436 (10%)
Table 1: Characteristics of all Australian PD patients who did and did not experience streptococcal peritonitis at any stage during the 
period 2003–2006. (Continued)BMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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Table 2: Antimicrobial agents prescribed in initial, second and third antibiotic regimens for streptococcal peritonitis episodes in 
Australian PD patients 2003–2006.
Antibiotic 1st regimen
(n = 287)
2nd regimen
(n = 163)
3rd regimen
(n = 37)
Cephazolin 131 (46%) 24 (15%) 3 (8%)
Vancomycin 129 (45%) 77 (47%) 17 (46%)
Gentamicin 203 (71%) 20 (12%) 7 (19%)
Other Aminoglycoside 1 (0.3%) 1 (1%) 0 (0%)
Ceftazidime 21 (7%) 3 (2%) 0 (0%)
Cefoxitin 9 (3%) 1 (1%) 0 (0%)
Cefipime 1 (0.3%) 1 (1%) 0 (0%)
Cephalothin 13 (5%) 5 (3%) 0 (0%)
Ceftriaxone 10 (3%) 4 (2%) 0 (0%)
Cefotaxime 0 (0%) 2 (1%) 0 (0%)
Cephalexin 13 (5%) 14 (9%) 4 (11%)
Other cephalosporin 4 (1%) 0 (0%) 0 (0%)
Ampicillin 3 (1%) 5 (3%) 2 (5%)
Amoxycillin 1 (0.3%) 9 (6%) 3 (8%)
Amoxycillin+clavulanate 6 (2%) 8 (5%) 3 (8%)
Dicloxacillin/Flucloxacillin 4 (1%) 3 (2%) 1 (3%)
Other penicillin 2 (1%) 2 (1%) 0 (0%)
Ciprofloxacin 17 (6%) 3 (2%) 4 (11%)
Metronidazole 2 (1%) 4 (3%) 1 (2%)
Cotrimoxazole 1 (0.3%) 0 (0%) 0 (0%)
Erythromycin 0 (0%) 1 (1%) 3 (1%)
Antifungal agent 2 (1%) 5 (3%) 3 (8%)
Other 3 (1%) 6 (4%) 0 (0%)
Results represent number of episodes treated with antibiotic (% of total treated with 1st, 2nd or 3rd line regimen). Note that values within each 
column add to more than 100% because of the use of combination antimicrobial regimens.BMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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our data. This may be due to the overall lower rates of
streptococcal peritonitis noted in our study or a change in
trend over time attributable to the use of disconnect sys-
tems. We did find streptococcal peritonitis was associated
with lower rates of relapse, catheter removal & permanent
haemodialysis transfer, which is supported by the litera-
ture to date [10,13].
Empirical antibiotic therapy in our study consisted of
either intraperitoneal cephazolin or vancomycin with
70% receiving concomitant gentamicin. When strepto-
cocci are identified by microscopy or culture, the ISPD
guidelines recommend intraperitoneal ampicillin and the
addition of gentamicin for synergy to cover enterococcal
species. Only 1% of patients in this study were initially
treated with ampicillin and, once culture results were
known, only 3% were subsequently treated with ampicil-
lin. Once streptococci were identified, a majority of
patients remained on a cephalosporin and one third were
swapped to vancomycin. These antibiotic regimens are
very similar to those reported by Shukla and coworkers
[1]. The conversion of a significant minority of patients in
our study to vancomycin may represent ease of adminis-
tration (requiring only once weekly bag dosing), develop-
ment of penicillin allergy, or in vitro resistance of isolated
streptococci to penicillins and cephalosporins. Unfortu-
nately, the ANZDATA Registry does not collect informa-
tion on antimicrobial susceptibilities of cultured micro-
organisms or the reasons for antibiotic selection.
The strengths of this study included its very large sample
size and inclusiveness. We included all patients receiving
PD in Australia across 66 centres during the study period,
such that a variety of centres were included with varying
approaches to the treatment of peritonitis. This greatly
enhanced the external validity of our findings. These
strengths should be balanced against the study's limita-
tions, which included limited depth of data collection.
ANZDATA does not collect important information, such
as the presence of concomitant exit site and tunnel infec-
tions, patient compliance, individual unit management
protocols, laboratory values (such as C-reactive protein
and dialysate white cell counts), severity of comorbidities,
species identification and antimicrobial susceptibilities of
Table 3: Treatment characteristics and clinical outcomes of PD-associated peritonitis due to streptococci or other organisms in 
Australia 2003–2006.
Outcome Streptococcal peritonitis
(n = 287 episodes)
Non-streptococcal peritonitis
(n = 3307 episodes)
P value
Treatment
Change to 2nd antibiotic regimen 163 (57%) 1847 (56%) 0.8
Time to 2nd antibiotic regimen 3 [1.75–5] 3 [2–5] 1.0
Change to 3nd antibiotic regimen 37 (13%) 460 (14%) 0.7
Time to 3rd antibiotic regimen 7.5 [5–9] 6 [4–10] 0.4
Total antibiotic treatment duration 13 [8–18] 14 [8–20] 0.10
Hospitalisation
Number (%) 212 (74%) 2292 (69%) 0.11
Duration (days) 5 [3–10] 6 [3–12] 0.002
Catheter removal
Number (%) 29 (10%) 746 (23%) <0.001
Time to occurrence (days) 7 [3–12] 6 [3–13] 0.8
Temporary haemodialysis
Number (%) 9 (3%) 143 (4%) 0.3
Time to occurrence (days) 3 [0.5–8] 6 [3–11.75] 0.08
Duration (days) 36 [9–89] 68.5 [24.75–104.75] 0.12
Permanent haemodialysis
Number (%) 25 (9%) 610 (18%) <0.001
Time to occurrence 8 [5–13] 7 [4–12] 0.4
Death
Number (%) 4 (1%) 78 (2%) 0.3
Time to death 7 [3–99.5] 13 [3.25–23.75] 0.7
Results are expressed as number (%) or median days [interquartile range].BMC Nephrology 2009, 10:19 http://www.biomedcentral.com/1471-2369/10/19
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isolated streptococci, antimicrobial dosages or routes of
antimicrobial administration. Even though we adjusted
for a large number of patient characteristics, the possibil-
ity of residual confounding could not be excluded. In
common with other Registries, ANZDATA is a voluntary
Registry and there is no external audit of data accuracy,
including the diagnosis of peritonitis. Consequently, the
possibility of coding/classification bias cannot be
excluded.
Conclusion
Streptococcal peritonitis is a not infrequent complication
of PD, although our analysis found a lower rate of strep-
tococcal peritonitis compared to previous studies (4.6%
vs 6–16%). The condition was more common in indige-
nous patients. When treated with either intraperitoneal
first-generation cephalosporins or vancomycin for an
average period of 2 weeks, streptococcal peritonitis was
associated with lower risks of relapse, catheter removal
and permanent haemodialysis transfer than other forms
of PD-associated peritonitis.
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